FP008 treatment for adults with advanced solid tumors
Official title: A Phase 1 First-In-Human Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics Activity of FP008 in Subjects With Advanced Solid Tumors
Run by Zhuhai Fapon Biopharma Co., Ltd. · NCT06990698 · Data updated 2026-11-12
This phase 1 trial will test FP008 to see if it is safe and shows signs of antitumor activity in adults with advanced solid tumors.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 108 (estimated) |
| Sponsor | Zhuhai Fapon Biopharma Co., Ltd. Industry-sponsored |
| Locations | 6 sites (Guangzhou, Guangdong and 5 other locations) |
| Status | Recruiting |
| Started | June 12, 2025 |
| Main results expected | May 2028 |
| Study ends | September 2028 |
| Registry record updated | September 30, 2026 |
| Trial ID | NCT06990698 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) with histologically confirmed unresectable or metastatic solid tumors, measurable disease by RECIST v1.1, ECOG performance status 0–1, life expectancy >3 months, adequate organ function, and disease progression after prior therapy are appropriate candidates.
✕Probably not a fit
Patients with ECOG >1, life expectancy ≤3 months, unresolved ≥Grade 2 toxicities from prior therapy, significant organ dysfunction, or who cannot comply with contraception requirements are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This first-in-human, multicenter, open-label phase 1 program gives FP008 by injection to adults with advanced, measurable solid tumors who have progressed on prior therapies. Part 1 uses dose-escalation to define tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and a recommended dose/schedule for expansion. Part 2 enrolls patients into dose-expansion cohorts to further characterize safety, PK/PD, immunogenicity, and preliminary efficacy at the selected dose(s). Investigators will use standard toxicity grading and RECIST v1.1 to monitor safety and tumor responses.
Why it matters
Potential benefit: If successful, FP008 could become a new treatment option that is tolerable and helps control or shrink advanced solid tumors.
How similar studies have gone: This is a first-in-human trial so FP008 has not been tested in people before, and while some first-in-human oncology agents have led to later approvals, many investigational agents do not.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Signed written ICF and be able to comply with the protocol. 2. Male and female subjects ≥18 years of age. 3. Life expectancy of \>3 months. 4. Laboratory values for sufficient organ function at screening. 5. Toxicity from prior antitumor treatment has resolved to ≤Grade 1 as defined by NCI CTCAE v5.0. 6. Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to the start of FP008. 7. Male or women of childbearing potential, if sexually active, must agree to use contraception considered adequate and appropriate by the investigator during the period of study drug administration and for at least 5 months after the last dose of FP008. 8. ECOG performance status of 0 to 1. 9. Histologically or cytologically confirmed malignancy diagnosis and at least one measurable documented advanced/unresectable or metastatic solid tumor as assessed by RECIST v1.1. 10. Documented progressive disease, refractory/resistance/intolerant to standard therapy (documented the reason(s) why they are intolerant to standard therapy by the investigator), or there is no standard therapy. Exclusion Criteria: 1. Subjects who have received other IL-10 agents. 2. A history of other malignancies other than basal cell carcinoma of skin, squamous cell carcinoma of skin, non-muscle invasive bladder cancer, thyroid papillary carcinoma or carcinoma in situ of the cervix that have been cured for 2 years after effective treatment. 3. Received live vaccine within 30 days prior to the first dose of FP008. 4. Not completely recovered from the effects of major surgery or significant traumatic injury at least 14 days before the first dose of FP008. 5. Known hypersensitivity to either the drug substances or inactive ingredient of FP008. 6. Subjects with diagnosis of immunodeficiency, organ transplant requiring immunosuppressive therapy, or allogeneic bone marrow or hematopoietic stem cell transplant. 7. Daily requirement for corticosteroids within 2 weeks prior to first dose of FP008. 8. Any other medical disorder, physical exam finding, laboratory finding, altered mental status, or psychiatric condition that the investigator considers unsuitable for participation in the study. 9. Cardiovascular dysfunction or clinically significant cardiac disease.
Where it's running
-
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China Recruiting -
Hubei Cancer Hospital
Wuhan, Hubei, China Recruiting -
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China Recruiting -
Shanxi Cancer Hospital
Taiyuan, Shanxi, China Recruiting -
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China Recruiting -
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China Recruiting
Study contacts
- Principal investigator: Aung Naing, MD — M.D. Anderson Cancer Center
- Study coordinator: Arron Wang
- Email: clinitrial.register@fapon.com
- Phone: 86-13926091581
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
AK157D1 injection for advanced solid tumors
A first-in-human Phase 1 study tests AK157D1 injection in adults with unresectable advanced solid tumors to see if it is safe and tolerable and to get early signs of how it behaves in the body and against tumors.
-
ABBV-253 in adults with advanced solid tumors
This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.
-
MK-2010 alone or with other treatments for advanced solid tumors
This trial tests MK-2010, by itself or with other cancer medicines, to see if it helps people with advanced solid tumors.
-
Whole-Body Infrared Heating for Advanced Solid Tumors
This study looks at how ET-SPACE whole-body infrared hyperthermia affects people with advanced solid tumors to see if it changes biology, symptoms, and safety.
-
MK-2010 with Sac-TMT in advanced solid tumors
This study tests MK-2010 combined with sacituzumab tirumotecan (sac-TMT) to see if it can help people with advanced solid tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.